Pfizer buys seat at biosimilars table next to Biocon

Biocon will continue to handle the development, manufacture and supply of biosimilar versions of its insulin and insulin analog products, following a deal with Pfizer. Analogs include Recombinant Human Insulin, Glargine, Aspart and Lispro. For its part, Pfizer will commercialize the products globally. Biocon announcement

Suggested Articles

Manufacturing

Concern for drug shortages grows as COVID-19 outbreak drags on

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

by Eric Palmer
Pills in pill container
Pharma Asia

Coronavirus poses threats to brand demand and generic supply

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

by Angus Liu
A closeup of a stock market ticker
Manufacturing

Manufacturing News of Note—WuXi Biologics restarts China sites

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.